早期症状性阿尔茨海默病抗Aβ抗体治疗的实用脑部MRI指南
Practical Brain MRI Guidelines for Anti-Aβ Antibody Treatment in Early Symptomatic Alzheimer's Disease.
作者信息
Kakeda Shingo, Miki Yukio, Kudo Kohsuke, Mori Harushi, Tokumaru Aya M, Abe Osamu, Aoki Shigeki
机构信息
Department of Radiology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.
Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
出版信息
Magn Reson Med Sci. 2025 Apr 5. doi: 10.2463/mrms.gl.2025-1000.
PURPOSE
These guidelines aim to support MRI diagnosis in patients receiving anti-amyloid β (Aβ) antibody treatment without restricting treatment eligibility.
MATERIALS AND METHODS
These guidelines were collaboratively established by Japan Radiological Society, The Japanese Society of Neuroradiology, and Japanese Society for Magnetic Resonance in Medicine by reviewing existing literature and the results of clinical trials.
RESULTS
Facility standards should comply with the "Optimal Use Promotion Guidelines" of Japan, and physicians should possess comprehensive knowledge of amyloid-related imaging abnormalities (ARIA) and expertise in brain MRI interpretation. The acquisition of knowledge regarding amyloid-related imaging abnormalities, brain MRI, anti-Aβ antibody introduction, and post-treatment diagnosis are also recommended.
CONCLUSION
These guidelines facilitate the accurate diagnosis and effective management of ARIA; ensure the safe administration of anti-Aβ drugs; and provide a framework for MRI facilities, includes staffing requirements and the use of MRI management systems.
目的
本指南旨在支持接受抗淀粉样β（Aβ）抗体治疗患者的MRI诊断，同时不限制治疗资格。
材料与方法
本指南由日本放射学会、日本神经放射学会和日本磁共振医学学会通过回顾现有文献和临床试验结果共同制定。
结果
设备标准应符合日本的“最佳使用促进指南”，医生应具备淀粉样蛋白相关成像异常（ARIA）的全面知识以及脑MRI解读专业知识。还建议获取有关淀粉样蛋白相关成像异常、脑MRI、抗Aβ抗体引入及治疗后诊断的知识。
结论
本指南有助于ARIA的准确诊断和有效管理；确保抗Aβ药物的安全给药；并为MRI设施提供框架，包括人员配备要求和MRI管理系统的使用。
Zotero 插件